Development of a surgical complexity score to predict postoperative morbidity following primary retroperitoneal sarcoma resection: a collaborative study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG)
Mark Fairweather(Brigham and Women's Hospital), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), Dimitri Tzanis(Université Paris Cité), Carol J. Swallow(University Health Network), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Vittorio Quagliuolo(Humanitas University), Kenneth Cardona(Emory University), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Marko Novak(Peter MacCallum Cancer Centre), John E. Mullinax(Moffitt Cancer Center), Joshua S. Jolissaint(Brigham and Women's Hospital), Valerie P. Grignol(Ohio State University Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Marco Rastrelli(Istituti di Ricovero e Cura a Carattere Scientifico), José Antonio González, Michelle Wilkinson(Royal Marsden Hospital), Elisabetta Pennacchioli(European Institute of Oncology), Magali Fau(University of Toronto), Sergio Valeri(Università Campus Bio-Medico), Fabio Tirotta Yvonne Schrage, David Gyorki(The University of Melbourne)
Cited by 6
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k